Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2015 | Clinical utility of flow cytometry in multiple myeloma

Bruno Paiva • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma

At the Myeloma 2015 meeting, Dr Bruno Paiva (University of Navarra, Spain) discusses the utility of flow cytometry as a therapeutic tool to identify precursor cells and detect the presence or absence of minimal residue disease (MRD) in multiple myeloma.

Speaker: Bruno Paiva

More from Bruno Paiva

MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study 2:22
MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study
Bruno Paiva • 6 Dec 2025
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma 2:25
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
Bruno Paiva • 6 Dec 2025
Comprehensive genomic characterization of CTCs in multiple myeloma 1:38
Comprehensive genomic characterization of CTCs in multiple myeloma
Bruno Paiva • 6 Dec 2025
What is the most effective method for detecting circulating tumor cells in multiple myeloma? 1:40
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
Bruno Paiva • 18 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals